TrialPath
Melanoma · Dallas

Melanoma clinical trials in Dallas

20 recruiting melanoma studies within range of Dallas. Click any trial for full eligibility criteria and contact info.

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774 · Cancer, Metastatic, Cancer, Cancer of Pancreas
Recruiting

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Phase
TypeObservational
AgeAny
WhereBirmingham, Alabama, United States + 67 more
SponsorMassive Bio, Inc.
Tap for details
Apply

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410 · Cutaneous Squamous Cell Carcinoma (CSCC)
Recruiting

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works

PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 48 more
SponsorRegeneron Pharmaceuticals
Tap for details
Apply

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

NCT05914116 · Advanced Solid Tumors
Recruiting

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 106 more
SponsorDualityBio Inc.
Tap for details
Apply

DESTINY-PANTUMOUR04

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer
Recruiting

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Phase
TypeObservational
Age18 Years – 130 Years
WhereBirmingham, Alabama, United States + 16 more
SponsorAstraZeneca
Tap for details
Apply

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379 · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult
Recruiting

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereBeverly Hills, California, United States + 5 more
SponsorNeonc Technologies, Inc.
Tap for details
Apply

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Recruiting

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalating doses of HMBD-501. The results of the dose escalation will determine the RP2D and dosing schedule of HMBD-501 to be administered in the Phase 2 part of the study. The primary objective of Phase 2 is to evaluate the preliminary clinical efficacy of HMBD-501 in dose expansion cohorts.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 6 more
SponsorHummingbird Bioscience
Tap for details
Apply

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NCT06326411 · Oncology, MEK Mutation, RAF Gene Mutation
Recruiting

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

PhasePhase 1
TypeInterventional
Age18 Years
WhereSan Francisco, California, United States + 22 more
SponsorNested Therapeutics, Inc
Tap for details
Apply

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314 · Advanced Melanoma
Recruiting

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

PhasePhase 3
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 210 more
SponsorImmunocore Ltd
Tap for details
Apply

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

PhasePhase 1
TypeInterventional
Age18 Years
WhereLos Angeles, California, United States + 15 more
SponsorOncoNano Medicine, Inc.
Tap for details
Apply

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983 · Advanced or Metastatic Solid Tumors
Recruiting

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

PhasePhase 1
TypeInterventional
Age18 Years
WhereBoston, Massachusetts, United States + 6 more
SponsorInnate Pharma
Tap for details
Apply

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

NCT06400550 · Melanoma (Skin)
Recruiting

The goal of this study is to observe metabolic features associated with human melanoma tumors.

Phase
TypeObservational
Age18 Years
WhereDallas, Texas, United States
SponsorUniversity of Texas Southwestern Medical Center
Tap for details
Apply

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Recruiting

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

PhasePhase 2 / Phase 3
TypeInterventional
AgeAny
WhereScottsdale, Arizona, United States + 32 more
SponsorReplimune, Inc.
Tap for details
Apply

A Study of VET3-TGI in Patients With Solid Tumors

NCT06444815 · Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Recruiting

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

PhasePhase 1
TypeInterventional
Age18 Years
WhereLos Angeles, California, United States + 6 more
SponsorKaliVir Immunotherapeutics
Tap for details
Apply

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

NCT04370587 · Solid Tumor, Melanoma, HNSCC
Recruiting

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 8 more
SponsorImmVira Pharma Co. Ltd
Tap for details
Apply

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

PhasePhase 3
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 65 more
SponsorImmatics US, Inc.
Tap for details
Apply

Dabrafenib and/or Trametinib Rollover Study

NCT03340506 · Melanoma, Non Small Cell Lung Cancer, Solid Tumor
Recruiting

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

PhasePhase 4
TypeInterventional
Age18 Years – 100 Years
WhereScottsdale, Arizona, United States + 27 more
SponsorNovartis Pharmaceuticals
Tap for details
Apply

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NCT06090266 · Cancer, Tumor, Solid, Malignant Neoplasm
Recruiting

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereAustin, Texas, United States + 3 more
SponsorOncoResponse, Inc.
Tap for details
Apply

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180 · Advanced Melanoma
Recruiting

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.

PhasePhase 3
TypeInterventional
Age12 Years
WhereGilbert, Arizona, United States + 80 more
SponsorReplimune, Inc.
Tap for details
Apply

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT02332668 · Melanoma, Lymphoma, Solid Tumor
Recruiting

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrollment of participants with solid tumors and participants 6 months to under 12 years old with melanoma were closed. With Amendment 13, enrollment was closed for participants with relapsed refractory classical Hodgkin lymphoma (rrCHL), microsatellite instabilty-high (MSI-H) solid tumors, tumor-mutational burden-high (TMB-H) solid tumors, and participants 12 years old to \<18 years old with advanced melanoma.

PhasePhase 1 / Phase 2
TypeInterventional
Age6 Months – 17 Years
WhereAurora, Colorado, United States + 16 more
SponsorMerck Sharp & Dohme LLC
Tap for details
Apply

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444 · Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma
Recruiting

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Phase
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 56 more
SponsorGuardant Health, Inc.
Tap for details
Apply